Table 1 Comparison of baseline characteristics in GCs group and non-GCs group
Characteristic | Patients, No. (%) | P | |
|---|---|---|---|
GCs (n = 342) | Non-GCs (n = 448) | ||
Age, years, median (IQR) | 55 (48–62.25) | 57 (49–64) | 0.050 |
Sex | 0.802 | ||
 Male | 219 (64.0) | 283 (63.2) | |
 Female | 123 (36.0) | 165 (36.8) | |
CEA, ng/ml, median (IQR) | 4.7 (2.30–11.90) | 3.70 (2.00–8.03) | 0.013 |
CA199, U/ml, median (IQR) | 12.83 (6.89–22.55) | 11.16 (6.09–19.91) | 0.087 |
Tumor location | 0.491 | ||
 Low | 161 (47.1) | 192 (42.9) | |
 Middle | 169 (49.4) | 240 (53.6) | |
 High | 12 (3.5) | 16 (3.5) | |
cT category | 0.080 | ||
 cT1-3 | 154 (45.0) | 174 (38.8) | |
 cT4 | 188 (55.0) | 274 (61.2) | |
cN category | 0.230 | ||
 cN0 | 29 (8.5) | 28 (6.3) | |
 cN+ | 308 (90.1) | 415 (92.6) | |
 Missing | 5 (1.5) | 5 (1.1) | |
Chemotherapy before NCRT |  < 0.001 | ||
 Yes | 55 (16.1) | 15 (3.3) | |
 No | 287 (83.9) | 433 (96.7) | |
CCT regimen |  < 0.001 | ||
 Xeloda | 151 (44.2) | 398 (88.8) | |
 XELOX | 137 (40.1) | 43 (9.6) | |
 FOLFOX4 | 35 (10.2) | 3 (0.7) | |
 De Gramont | 19 (5.6) | 4 (0.9) | |
SIB to GTV |  < 0.001 | ||
 Yes | 281 (82.2) | 435 (97.1) | |
 No | 61 (17.8) | 13 (2.9) | |
Radiotherapy technology |  < 0.001 | ||
 IMRT | 210 (61.4) | 347 (77.5) | |
 3D-CRT | 123 (36.0) | 79 (17.6) | |
 VAMT | 9 (2.6) | 22 (4.9) | |
Days of radiotherapy, median (IQR) | 37 (35–39) | 37 (35–39) | 0.849 |
Interval between radiotherapy and surgery, day, median (IQR) | 61 (55–66) | 64 (60–71) |  < 0.001 |